Novel treatment of recurrent orbital venolymphatic malformation with sirolimus and rivaroxaban

ABSTRACT

Orbital venolymphatic malformations are rare vascular malformations that typically appear early in life and harbor acute and chronic threats to vision. Historically, there are four categories of management: observation, medication, sclerotherapy, and surgery. Currently, there is neither a gold standard for treatment nor randomized control trials comparing treatments.

The authors present a 20-year-old male who presented with spontaneous hemorrhage of an orbital venolymphatic malformation occurring with increased frequency and involving more of the posterior orbit. Surgery and sclerotherapy were not feasible options due to the extensive intraorbital and intracranial involvement of the venolymphatic malformation. Systemic steroids treated symptoms but was not curative. To this end, a combination of sirolimus, an mTOR inhibitor, and rivaroxaban, a factor Xa inhibitor, were used to reduce the size of the lesion and minimize the risk of thromboembolic events. This treatment has successfully kept the patient’s symptoms in remission for greater than 2 years.

Disclosure statement

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the article.

Disclaimer

The views expressed in this article are those of the author(s) and do not reflect the official policy of the Department of the Army/Navy/Air Force, Uniformed Services University, Defense Health Agency, Department of Defense, or the U.S. Government. Discussion or mention of any commercial products or vendor names within this publication does not constitute endorsement or implied endorsement on the part of the Department of Defense or any other organization as stated above.